Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Protein subunit |
Clinical data | |
Other names | SARS-CoV-2 Sclamp |
Routes of administration | Intramuscular |
Legal status | |
Legal status |
|
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
![]() |
V451 was a COVID-19 vaccine candidate developed by the University of Queensland and the Australian pharmaceutical company CSL Limited. The vaccine candidate used the University of Queensland's molecular clamp technology[1] and the MF59 adjuvant.[2]